Hypoxia-Driven Mechanisms of Drug Resistance in Prostate Cancer
Cancers · 11.03.2026 · 18 (6) · 899
DOI: 10.3390/cancers18060899 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 11.03.2026. Verfasst von Madeline R Ressel und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, The University of Arizona, Tucson, AZ 85721, USA. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 197 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: United States Department of Defense, Department of Defense Prostate Cancer Research.
Abstract (Originalsprache)
Prostate cancer is the most common non-cutaneous malignancy in men and is the second leading cause of male cancer-related mortality. Unlike many cancers, prostate cancer lacks clear genetic driver mutations, suggesting that factors in the tumor microenvironment contribute to the genesis and progression of this disease. Hypoxia, or a physiological state of low oxygen, is a universal characteristic of solid tumors that enhances disease progression and therapeutic resistance. Prostate cancer develops in a hypoxic microenvironment and primarily metastasizes to bone, where oxygen availability is similarly limited. Therefore, hypoxia is a major obstacle to the effective treatment of prostate cancer across all disease stages. Clinically, hypoxia is correlated with worse patient outcomes, largely because it drives resistance to the frontline therapies used to treat both primary and metastatic prostate cancer. Despite the established role of hypoxia in prostate cancer progression and drug resistance, it has not been successfully targeted therapeutically. Emerging evidence indicates that exposure to distinct temporal patterns of hypoxia (acute, cyclic, and chronic) elicits unique cellular adaptations that dictate tumor growth and survival. This review synthesizes current evidence regarding the role of hypoxia in promoting resistance to therapy in prostate cancer.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Urology, The University of Arizona, Tucson, AZ 85721, USA.
- Cancer Biology Graduate Interdisciplinary Program, University of Arizona Cancer Center, Tucson, AZ 85724, USA.
- Department of Cellular & Molecular Medicine, The University of Arizona, Tucson, AZ 85721, USA.
- Department of Biochemistry and Molecular Biology, The Medical University of South Carolina, Charleston, SC 29425, USA.
ORCID-Profile: Madeline R Ressel, Caitlyn E Flores, Noel A Warfel
Förderung
- United States Department of Defense
- Department of Defense Prostate Cancer Research
Zitieren
APA
Ressel, M. R., Flores, C. E., & Warfel, N. A. (2026). Hypoxia-Driven Mechanisms of Drug Resistance in Prostate Cancer. Cancers, 18(6), 899. https://doi.org/10.3390/cancers18060899
Vancouver
Ressel MR, Flores CE, Warfel NA. Hypoxia-Driven Mechanisms of Drug Resistance in Prostate Cancer. Cancers. 2026;18(6):899. doi:10.3390/cancers18060899
BibTeX
@article{Ressel2026,
author = {Ressel, Madeline R and Flores, Caitlyn E and Warfel, Noel A},
title = {Hypoxia-Driven Mechanisms of Drug Resistance in Prostate Cancer},
journal = {Cancers},
year = {2026},
volume = {18},
number = {6},
pages = {899},
doi = {10.3390/cancers18060899}
}
EUVIMED